BIO 2025 Key takeaways
Key Takeaways from BIO 2025: What’s Next for Biotech and Clinical Trials What’s next for biotech? If you walked the halls of BIO 2025 in Boston, the answer was everywhere—in AI-driven drug development, smarter clinical trial strategies, and a renewed focus on execution over hype. Cromos Pharma’s Business Development Director, Nicole Brenna, was on the ground meeting partners and tracking the trends that are shaping the future Read more
Rescuing Failing Cancer Trials with the Right Oncology CRO Discover why oncology trials fail and how the right oncology CRO can step in to rescue struggling studies, improve enrollment, and stabilize operations. Read more
Clinical Research Focus. 41st Edition EMA Backs New CAR-T Therapy for Adult Acute Lymphoblastic Leukemia The EMA has recommended conditional approval of Aucatzyl, a CAR T-cell therapy for adults 26+ with relapsed or refractory B-cell ALL. The treatment reprograms a patient’s own immune cells to target cancer and has shown strong remission results in trials. If approved by the European Read more
Top 10 ASCO 2025 insights for oncology clinical trial sponsors – Cromos Pharm
Post-ASCO 2025 Insights: What Oncology Sponsors Need To Know The 2025 ASCO Annual Meeting, held in Chicago, IL from May 30 to June 3, featured more than 6,000 abstracts. Below are 10 of the most strategic and actionable insights for oncology sponsors from this year’s event:  1. Meta-Analysis of Surrogate Endpoints vs OS/QOL A poster summary (Abstract 11015) examined ~800 phase III oncology trials Read more

Schedule a meeting

We are excited to connect with you, understand your goals, and explore how we can support your needs.

Contact us